menu
    • menu

    Company profile for Ractigen Therapeutics

    NEW Drugs in Dev: 5
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ractigen Therapeutics is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is deve...
    Ractigen Therapeutics is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ractigen TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    Bldg.18, Rudong Life & Health Industry Park, 888 Zhujiang Rd, Rudong, Nantong,...
    Telephone
    Telephone
    (+86) 513-81996959
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ractigen.com/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ractigen-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ractigen

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    MAGHREB Pharma Expo

    MAGHREB Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    MAGHREB Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ractigen Secures NMPA IND for RAG-01 Phase II in NMIBC
    Ractigen Secures NMPA IND for RAG-01 Phase II in NMIBC

    19 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ractigen-therapeutics-announces-china-nmpa-ind-approval-for-phase-ii-clinical-trial-of-sarna-therapy-rag-01-in-non-muscle-invasive-bladder-cancer-302718706.html

    PR NEWSWIRE
    19 Mar 2026
    Share Share
    Ractigen Announces 1st Patient Dosed in Ph 2 Trial of RAG-17
    Ractigen Announces 1st Patient Dosed in Ph 2 Trial of RAG-17

    13 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ractigen-therapeutics-announces-first-patient-dosed-in-phase-ii-clinical-trial-of-rag-17-for-sod1-als-302659587.html

    PR NEWSWIRE
    13 Jan 2026
    Share Share
    Ractigen Initiates First Patient Dosing In IIT Study Of RAG-18
    Ractigen Initiates First Patient Dosing In IIT Study Of RAG-18

    12 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/ractigen-therapeutics-doses-first-patient-in-iit-study-of-rag-18-a-potential-game-changing-sarna-therapeutic-for-duchenne-muscular-dystrophy-302640199.html

    PR NEWSWIRE BIO
    12 Dec 2025
    Share Share
    Ractigen's RAG-17 ALS Data Impresses at AAN 2025: Wins Top Award
    Ractigen's RAG-17 ALS Data Impresses at AAN 2025: Wins Top Award

    09 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ractigens-rag-17-als-data-shines-at-aan-2025-earns-top-award-phase-i-advances-302424420.html

    PR NEWSWIRE
    09 Apr 2025
    Share Share
    Ractigen's RAG-01 Shows Complete Responses in Ph I NMIBC Trail
    Ractigen's RAG-01 Shows Complete Responses in Ph I NMIBC Trail

    24 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ractigens-rag-01-shows-promising-early-complete-responses-in-phase-i-nmibc-trial-data-presented-at-eau-2025-302409218.html

    PR NEWSWIRE
    24 Mar 2025
    Share Share
    Ractigen Founder Dr. Long-Cheng Li Wins Life Science Award
    Ractigen Founder Dr. Long-Cheng Li Wins Life Science Award

    31 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ractigen-therapeutics-founder-dr-long-cheng-li-awarded-2024-life-science-ice-breaking-award-302340610.html

    PR NEWSWIRE
    31 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search